1. Home
  2. TRT vs BNR Comparison

TRT vs BNR Comparison

Compare TRT & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trio-Tech International

TRT

Trio-Tech International

HOLD

Current Price

$9.23

Market Cap

105.0M

Sector

Technology

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$8.95

Market Cap

94.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRT
BNR
Founded
1958
2014
Country
United States
China
Employees
N/A
667
Industry
Industrial Machinery/Components
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
105.0M
94.4M
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
TRT
BNR
Price
$9.23
$8.95
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
422.9K
15.0K
Earning Date
05-13-2026
06-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$32,462,000.00
N/A
Revenue This Year
N/A
$111.65
Revenue Next Year
N/A
N/A
P/E Ratio
$495.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.42
$5.31
52 Week High
$21.38
$41.72

Technical Indicators

Market Signals
Indicator
TRT
BNR
Relative Strength Index (RSI) 40.89 42.06
Support Level $6.47 $8.34
Resistance Level $9.50 $10.00
Average True Range (ATR) 1.02 0.85
MACD -0.06 -0.01
Stochastic Oscillator 0.00 6.41

Price Performance

Historical Comparison
TRT
BNR

About TRT Trio-Tech International

Trio-Tech International is a provider of reliability test equipment and services to the semiconductor and other industries. Its customers are from automotive electronics, industrial electronics, computing and data storage, consumer electronics, and communication markets. The company operated its business in two segments: Semiconductor Back-end Solutions and Industrial Electronics. Geographically, the company operates in the United States (U.S), Singapore, Malaysia, Thailand and China.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

Share on Social Networks: